Cyclin D1 expression in acute leukemia

被引:22
作者
Aref, S [1 ]
Mabed, M
El-Sherbiny, M
Selim, T
Metwaly, A
机构
[1] Mansoura Fac Med, Dept Clin Pathol, Hematol Unit, Mansoura, Egypt
[2] Mansoura Fac Med, Oncol Unit, Mansoura, Egypt
[3] Cairo Univ, NCI, Dept Med Oncol, Cairo, Egypt
关键词
cyclin D1; flow cytometry; AML; ALL;
D O I
10.1080/10245330500322321
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Disorders of the cell cycle regulatory machinery play a key role in the pathogenesis of cancer. Over expression of cyclin D1 protein has been reported in several solid tumors and certain lymphoid malignancies, but little is known about the involvement of cyclin D1 in acute leukemia. Patients and methods: In this study, we analyzed the expression of cyclin D1 at protein level in, 40 newly diagnosed patients with acute myeloid leukemia (AML), 10 patients with acute lymphoblastic leukemia ( ALL), and 11 normal controls using flow cytometry. Results: The expression of cyclin D1 was not significantly different in AML group as compared to normal controls. On the other hand, over expression of cyclin D1 was evident in ALL group (4/10) as compared to that in healthy control. The ALL cases with cyclin D1 over expression were significantly correlated to blast cell counts in the peripheral blood and bone marrow ( BM) but not with hemoglobin level, WBC, and platelets count. The ALL group with lymphadenopathy and organomegaly express significantly higher cyclin D1 over expression as compared to those without. Conclusion: The biological value of cyclin D1 over expression might be different in AML and ALL.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 14 条
[1]
Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer [J].
Barbieri, F ;
Lorenzi, P ;
Ragni, N ;
Schettini, G ;
Bruzzo, C ;
Pedullà, F ;
Alama, A .
ONCOLOGY, 2004, 66 (04) :310-315
[2]
Cycling to cancer with cyclin D1 [J].
Diehl, JA .
CANCER BIOLOGY & THERAPY, 2002, 1 (03) :226-231
[3]
Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies [J].
Elnenaei, MO ;
Jadayel, DM ;
Matutes, E ;
Morilla, R ;
Owusu-Ankomah, K ;
Atkinson, S ;
Titley, I ;
Mandala, EM ;
Catovsky, D .
LEUKEMIA RESEARCH, 2001, 25 (02) :115-123
[4]
The activities of cyclin D1 that drive tumorigenesis [J].
Ewen, ME ;
Lamb, J .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (04) :158-162
[5]
Minireview: Cyclin D1: Normal and abnormal functions [J].
Fu, MF ;
Wang, CG ;
Li, ZP ;
Sakamaki, T ;
Pestell, RG .
ENDOCRINOLOGY, 2004, 145 (12) :5439-5447
[6]
Ikehara M, 2003, ONCOL REP, V10, P137
[7]
Katayama Y, 2004, INT J ONCOL, V25, P579
[8]
Sauerbrey A, 1999, ANTICANCER RES, V19, P645
[9]
Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels [J].
Specht, K ;
Haralambieva, E ;
Bink, K ;
Kremer, M ;
Mandl-Weber, S ;
Koch, I ;
Tomer, R ;
Hofler, H ;
Schuuring, E ;
Kluin, PM ;
Fend, F ;
Quintanilla-Martinez, L .
BLOOD, 2004, 104 (04) :1120-1126
[10]
Cyclin DI overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients [J].
Stendahl, M ;
Kronblad, Å ;
Rydén, L ;
Emdin, S ;
Bengtsson, NO ;
Landberg, G .
BRITISH JOURNAL OF CANCER, 2004, 90 (10) :1942-1948